Evolent Health (EVH) Expected to Announce Earnings on Thursday

Evolent Health (NYSE:EVH) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Evolent Health to announce earnings of ($0.01) per share and revenue of $597.6970 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Evolent Health (NYSE:EVH) last announced its earnings results on Thursday, May 7th. The technology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $496.25 million during the quarter, compared to analysts’ expectations of $534.00 million. Evolent Health had a positive return on equity of 0.36% and a negative net margin of 26.29%.Evolent Health’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the business posted $0.06 EPS. On average, analysts expect Evolent Health to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Evolent Health Trading Down 3.0%

NYSE EVH traded down $0.10 during trading on Tuesday, hitting $3.04. The stock had a trading volume of 430,460 shares, compared to its average volume of 3,001,658. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 2.46. The company has a market capitalization of $342.50 million, a PE ratio of -0.64 and a beta of 0.76. The firm has a 50 day moving average price of $4.79 and a 200 day moving average price of $3.73. Evolent Health has a twelve month low of $2.10 and a twelve month high of $10.08.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EVH. Weiss Ratings cut shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 21st. Canaccord Genuity Group increased their target price on shares of Evolent Health from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Truist Financial cut shares of Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a research report on Tuesday, June 30th. TD Cowen dropped their price target on shares of Evolent Health from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Finally, Needham & Company LLC boosted their price target on shares of Evolent Health from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $6.16.

Institutional Trading of Evolent Health

Large investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC lifted its stake in Evolent Health by 4,000.0% in the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after acquiring an additional 4,000 shares during the last quarter. Strs Ohio purchased a new stake in shares of Evolent Health in the 1st quarter valued at approximately $47,000. Headlands Technologies LLC purchased a new stake in shares of Evolent Health in the 2nd quarter valued at approximately $58,000. Quantbot Technologies LP acquired a new stake in shares of Evolent Health in the 3rd quarter valued at $88,000. Finally, Caxton Associates LLP acquired a new stake in shares of Evolent Health in the 3rd quarter valued at $93,000.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.